Unbiased human genomic characterization of polyglutamine disorder genes to guide biological understanding and therapeutic strategies

Kevin Lucy Namuli,[1,2] Britt I. Drögemöller,[3] Galen E.B. Wright,[1,2,3]

Author affiliations:

[1]Department of Pharmacology and Therapeutics, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.

[2]PrairieNeuro Research Centre, Kleysen Institute for Advanced Medicine, Health Sciences Centre and Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada

[3]Department of Biochemistry and Medical Genetics, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.

Correspondence to: Galen E.B. Wright
Department of Pharmacology and Therapeutics
University of Manitoba
Winnipeg, MB, Canada
Phone: +1 (204) 272-3130
galen.wright@umanitoba.ca

Running title: Genomic Insights Guide PolyQ Therapeutics

Financial Disclosure/Conflict of Interests: The authors report no competing interests.

Funding Sources: Natural Sciences and Engineering Research Council of Canada (Canada Research Chairs Initiative CRC-2019-145 and Discovery Grant Program RGPIN-2022-04509), Health Sciences Centre Foundation Winnipeg, Canadian Institutes of Health Research (Canada Research Chairs Initiative CRC-2023-00351), Research Manitoba and Rady Faculty of Health Sciences, University of Manitoba.

Abstract

Background: Polyglutamine (polyQ) disorders, such as Huntington disease (HD) and several spinocerebellar ataxias, are severe neurological disorders caused by glutamine codon repeat expansions. These conditions lack effective treatments, with therapeutic research focused on pathogenic gene knockdown.

Objectives: We aimed to profile these genes using diverse human genomic data to inform therapeutic strategies by identifying new biology and assessing the potential on-target effects of knocking down these genes.

Methods: We conducted an unbiased phenome-wide study to identify human traits and diseases linked to polyQ disorder genes (Open Targets L2G>0.5). Network analyses explored shared trait associations and overlapping biological processes among these genes. Lastly, we assessed the theoretical druggability of polyQ disorder genes using recently identified features predictive of clinical trial success and compared them to repeat expansion (HD) modifier genes.

Results: We identified 215 human phenotype/polyQ disorder gene associations from 3,095 studies, indicating potential adverse effects from gene knockdown. Shared trait associations among genes suggested overlapping biological processes despite distinct functions. Drug target profile analysis revealed unfavorable risk profiles for polyQ disorder genes, particularly *ATN1*, *ATXN1*, *ATXN7*, and *HTT*, due to genomic features such as constraint, molecular interactions, and tissue specificity. PolyQ disorder genes also showed significantly more safety-related risks than HD genetic modifier genes ($P=7.03\text{x}10^{-3}$).

Conclusion: Our analyses emphasize the pleiotropic nature of polyQ disorder genes, highlighting their potential risks as drug targets. These findings reinforce the importance of exploring alternative therapeutic strategies, such as targeting genetic modifier genes, as well as allele-selective approaches, to mitigate these challenges.

Introduction

Polyglutamine (polyQ) disorders are a group of ten heritable neurodegenerative conditions characterized by repeat expansions of the glutamine codon in distinct genes.[1] These include Huntington disease (HD), spinal and bulbar muscular atrophy (SBMA), dentatorubral-pallidoluysian atrophy (DRPLA), and several spinocerebellar ataxias (i.e., SCAs: 1-3, 6, 7 and 17).[1] Collectively, they affect approximately 1-10 individuals per 100,000 people, contributing significantly to the increasing burden of neurological disorders globally.[2]

To date, some progress has been made in elucidating the pathogenic mechanisms of polyQ disorders. Unfortunately, these disorders remain without a cure, with current pharmacological treatments focused on alleviating the symptoms.[3,4] While gene knockdown strategies, such as antisense oligonucleotides (ASOs), have been the focus of current research, and some of these ASOs have advanced to clinical trial stages, efficacy and safety issues remain substantial barriers to their clinical implementation.[3,5–7] For example, the ASO tominersen demonstrated adverse events and failed to achieve efficacy. As tominersen suppresses the production of wild-type *HTT*,[8,9] this disrupts normal gene function, highlighting the challenges associated with the therapeutic targeting of polyQ genes. This is particularly important given that all polyQ disorders present in an autosomal dominant manner, except for SBMA.

The role of adverse events in clinical trial failures underscores the importance of understanding the biological consequences of targeting specific genes when designing therapeutics.[10] In line with this, Plenge *et al.*[11] highlighted the significance of evaluating potential adverse clinical consequences *a priori* by identifying human phenotypes associated with genetic variation related to drug target genes.[11] The increasing availability of extensive genome-wide association studies (GWAS) and related repositories, assisted by fine-mapping techniques that link genetic associations to suspected causal genes,[12,13] allows for systematic and unbiased identification of gene-trait links. For example, we previously showed that common *HTT* genetic variation is associated with cognitive function in large human cohorts.[14,15]

Associations between polyQ disorder genes and human traits can also provide insights into the biological processes that these genes are involved in, aiding in the identification of additional

potential therapeutic targets. Several studies have demonstrated that drugs with prior genetic

evidence supporting the role that the targeted gene plays in the clinical phenotype being treated

are more likely to succeed in clinical trials.[13,16–20] Notably, a recent study also identified additional

genetic factors associated with clinical trial outcomes,[19] showing that genes displaying human

genetic constraint, several interacting partners and broad gene expression were associated with

clinical trial stoppage. These studies illustrate the importance of incorporating human genomic

information into drug development pipelines.

The challenges highlighted above underscore the need to comprehensively evaluate polyQ disorder

genes to identify potential on-target effects and investigate genomic features associated with

therapeutic failures. Here, we aimed to characterize polyQ disorder genes using extensive human

genomic data to inform therapeutic studies and disease biology. First, we analyzed and prioritized

human trait and disease associations with common genetic variation in polyQ disorder genes using

large repositories. We unbiasedly profiled important human genomic information through this

approach to identify potential on-target effects. We also uncovered unique and shared biological

features by examining phenotypes associated with these genes outside of the polyQ disorders

themselves. Finally, we evaluated the theoretical druggability of the polyQ disorder genes, ranking

them according to features related to clinical trial success and comparing them to the repeat

expansion modifier genes that influence disease onset. Our comprehensive analysis enhances our

understanding of the underlying biology of polyQ disorders and offers potential insights into the

consequences of targeting the associated genes for polyQ disorder therapeutics. The findings from

our study have broad relevance to therapeutic strategies for other repeat expansion disorders, of

which more than 50 have been identified.

Material and Methods

Ethical approval and gene selection

Ethical approval was obtained from the University of Manitoba Bannatyne Research Ethics Board

(H2022:354 HS25743). We profiled all known polyQ disorder genes (n=10, i.e., *AR*, *ATN1*,

ATXN1, *ATXN2*, *ATXN3*, *ATXN7*, *CACNA1A*, *HTT*, *TBP* and *THAP11*). For GWAS-based

analyses, we excluded *AR* because it is located on the X chromosome, and most current GWAS do

not include this information.

Identification of human traits and diseases associated with polyQ disorder genes

To identify human traits and diseases associated with the polyQ disorder genes beyond their

primary disorders, an unbiased, comprehensive phenome-wide study was conducted by analyzing

data from the Open Targets Genetics database (OTG) (version 8).[12] This repository contains

approximately 132,893 curated GWAS association signals from various studies and genomic

biobanks (e.g., FinnGen and UK Biobank), including 8,317 human GWAS summary statistics

(extracted January 2024). To curate OTG data, we used the related application programming

interface, implemented using GraphQL v2.0[12] and executed in R 4.3.3.

We accessed polyQ disorder gene data using Ensembl identifiers.[21] We identified human traits

where significant associations could be attributed to polyQ disorder genes using the locus-to-gene

(L2G) fine-mapping tool.[22] L2G is designed to refine genome-wide significant GWAS signals

($P<5 \times 10^{-8}$), identifying likely causal genes attributed to these signals.[12] This tool uses a scoring

metric that quantifies the strength of evidence for gene-trait associations, ranging from 0 to 1.[12]

Higher scores signify increased support for a particular gene-trait association. Traits overlapping

with the polyQ disorder genes with L2G>0.5 were kept for further analysis as recommended by

the developers of this tool.[22]

Finally, to examine other severe Mendelian disorders and other phenotypes associated with polyQ

disorder genes outside of the canonical polyQ disorder, we profiled the Online Mendelian

Inheritance in Man (OMIM) database.[23] We analyzed the OMIM genemap2 dataset (accessed June

2022) containing 5,779 phenotype entries.

Assessing shared traits among polyQ disorder genes

To investigate whether polyQ disorder genes are linked to shared traits and the degree of this

overlap, we performed a network analysis using *ggraph* (version 2.1.0) and *arcdiagram* (version

0.1.12) in R. All gene-trait associations with an L2G>0.5 were included in the network analysis.

In the resulting network, each node represented a polyQ disorder gene, and each edge (link)

represented a bidirectional relationship shared between two genes. This network analysis aimed to

identify networks of genes linked to particular traits, thereby providing insights into underlying
mechanisms and shared biology.

Prioritization of informative L2G-significant human trait associations for polyQ disorder
genes

To prioritize individual traits and disease signals for the polyQ disorder genes, count-based traits
(e.g., blood cell types) were removed. This was performed to minimize non-specific signals, as
such traits are associated with numerous generic associations across the genome. Further, we
restricted our analyses to include only gene-trait pairs derived from peer-reviewed PubMed studies
to ensure the robustness of study findings.

Variant annotation and unique signal identification

We annotated the predicted functional effect of index variants related to GWAS trait signals to
understand their potential mechanistic contribution to the observed gene-trait associations.
Ensembl Variant Effect Predictor was used to identify the *most severe* consequence flag related to
each polyQ disorder gene. SpliceAI was used to predict whether the variants alter splicing.[24]
Genotype-Tissue Expression (GTEx) data were assessed to determine whether variants were
linked to gene expression changes of the related polyQ disorder genes. Further, we identified
independent signals at each gene by considering linkage disequilibrium (LD) between index
variants. Independent signals, defined as haplotypes, were determined by pruning index variants
with $r^2>0.5$ using the 1,000 Genomes European super-population with LDLink SNPClip.[25] Each
haplotype was described as a set of variants in LD (i.e., $r^2>0.5$) with each other. A single tag variant
was considered a proxy for all the variants in high LD and was used to capture these haplotypes.
The Finnish population was excluded from this analysis to minimize potential confounding factors
from extended haplotype blocks.[26] Resulting haplotypes were assigned to prioritized polyQ
disorder gene-trait pairs to determine unique signals at each locus.

Assessment of the theoretical druggability and risk profiles of the polyQ disorder genes

To thoroughly evaluate polyQ disorder genes for theoretical druggability and drug target profiles
related to the risk of clinical trial failure, we assessed recently identified features associated with
clinical trial success.[19] Genes were categorized as favorable/unfavorable under each category
based on previously determined thresholds.[19] The following features were included:

(i)   <u>Genomic constraint</u>: We examined genes' tolerance to loss-of-function mutations using

123   sequencing data from the Genome Aggregation (gnomAD) Database, which contains

124   125,748 exomes and 15,708 genomes (gnomAD v2.1.1; accessed July 2022).[27] We

125   used the probability of loss-of-function intolerance (pLI) metric, which ranges from 0

126   to 1, with more constrained genes having higher scores. Genes with a high degree of

127   constraint were categorized as unfavourable, indicated by a rank greater than 0.9

128   (corresponding to *"extremely loss of function intolerant"* genes).[28]

129   (ii)   <u>Tissue expression</u>: We accessed RNA tissue specificity data from the Human Protein

130   Atlas (HPA) database (accessed February 2023),[29] which uses data from the HPA and

131   GTEx to classify genes into five categories (i.e., *"tissue enriched"*, *"group enriched"*,

132   *"tissue enhanced"*, *"low tissue specificity"* and *"not detected"*) based on fold change

133   in mRNA expression across 37 organ systems.[30] Genes whose RNA tissue specificity

134   was classified as *"low tissue specificity"* were ranked unfavorable as they are broadly

135   expressed.

136   (iii) <u>Molecular interactions (MI)</u>: We used the Open Targets Platform to access data from

137   the IntAct database[31] related to MI evidence for the genes (accessed October 2024).

138   We used the MI score, which ranges from 0 to 1 (scores closer to 1 are higher

139   confidence) and is built using diverse data (i.e., publications, experimental detection

140   methods, and interaction types).[32] Genes with more than ten interacting partners with

141   MI scores exceeding 0.42 (considered high confidence[19]) were unfavorable.

142   (iv)   <u>Druggability evidence</u>: We assessed the Drug Gene Interaction Database (accessed July

143   2024)[33] to identify any known or potentially druggable genes among the polyQ disorder

144   genes. We assigned a favorable "*druggable any*" metric to polyQ disorder genes that

145   had any known or predicted evidence of interaction with drugs from this database.

Finally, we compared the number of unfavorable genomic features associated with increased

safety-related risk (i.e., constraint, expression and interactions) to these same metrics reported in

our recent analysis of HD modifier genes[34] using the Wilcoxon test accompanied by the calculation

of the effect size (r) to quantify the magnitude of the observed difference. This analysis aimed to

assess whether targeting one of these gene sets presents a theoretically greater safety risk than the

other. $P<0.05$ was considered significant in these analyses.

Data sharing

The data used in the analyses described in this study are publicly accessible to researchers through the consortia that generated them. Analysis scripts for data accession, analysis and visualization are accessible at https://github.com/Wright-Lab-Neurogenomics-Research/polyQ_genes_characterization_analyses

Results

Profiling polyQ disorder genes for associations with common human traits and diseases

We identified 3,095 association signals (1,467 unique traits) surrounding polyQ disorder genes from the OTG database. These traits were distributed across 20 categories based on health conditions or biological processes, with the broad *measurement* category containing the most associations (n=2,521)*.* Applying a filtering threshold of L2G>0.5 retained seven polyQ disorder genes (i.e., *ATXN1*, *ATXN2*, *ATXN3*, *ATXN7*, *CACNA1A*, *HTT* and *TBP*) and identified 215 gene-trait pairs (149 unique traits), signifying associations with strong evidence for polyQ disorder gene involvement (**Figure 1**). *ATXN1* had the highest number of L2G>0.5 significant traits reported (n=57), predominantly related to hematological (measurement) phenotypes. *ATXN3* and *TBP* were exclusively linked to hematological phenotypes, while *ATXN7* was associated solely with disease-related phenotypes. Network analysis of the 215 polyQ disorder gene-trait pairs with L2G>0.5 revealed that five polyQ disorder genes shared phenotypic traits. *TBP* and *CACNA1A* did not share traits with any polyQ disorder genes. *ATXN1* had the greatest traits shared with the other polyQ disorder genes. *HTT* and *ATXN1* displayed the most shared traits, including educational attainment and cognitive ability, in addition to neutrophil and white blood cell counts.

We applied further prioritization steps to obtain high confidence and informative traits linked to polyQ disorder genes, including removing count-based terms and studies not found in PubMed. These analyses retained 46 significant traits (L2G>0.5) and five polyQ disorder genes: *HTT, ATXN1, ATXN2, ATXN7*, and *CACNA1A* (**Figure 2**). Furthermore, filtering out duplicate traits for each gene retained 37 unique gene-trait associations. These informative trait associations represent diverse disease phenotypes, including neuropsychiatric traits (e.g., *HTT*-depression, *CACNA1A*-positive affect, *ATXN7*-schizophrenia), metabolic disorders (e.g., *ATXN2*-type 1 diabetes,

HTT/ATXN7-type 2 diabetes) and autoimmune disorders (e.g., *ATXN1*-multiple sclerosis, *ATXN1*-

systemic lupus erythematosus). Additionally, they include several non-neurological traits or

diseases, such as *ATXN1*-atrial fibrillation, *ATXN1*-/*ATXN7*-breast cancer, and *ATXN7*-cataracts.

PolyQ disorder genes, such as *ATXN1* and *HTT,* were associated with non-pathogenic neurogenetic

traits, including educational attainment, cognitive ability, and aging. This collective observation

highlights the pleiotropic features related to these genes outside of polyQ pathobiology.

Investigation and annotation of the variants linked to unique polyQ disorder gene-common

trait associations

The index variants linked with the high-confidence unique traits associated with the polyQ disorder

genes fall into three categories: intronic (*n*=26), splice (*n*=1), and variants located in untranslated

regions (*n*=1) (**Figure 2**). Notably, all traits associated with the splice and untranslated region

variants were annotated to *HTT*. In contrast, traits related to the remaining polyQ disorder genes

(i.e., *CACNA1A, ATXN1, ATXN2* and *ATXN7*) were exclusively associated with intronic variants.

The *HTT* splice variant showed associations with educational attainment and its noncognitive

aspects. *ATXN7* was associated with several pathogenic traits, including type 2 diabetes,

schizophrenia, breast cancer and cataracts, each associated with a unique variant (total *n=4*).

The 37 unique gene-trait associations arose from 30 distinct signals. A variant located in the

untranslated region in *HTT* was associated with the highest number of distinct traits (*n*=5),

including type 2 diabetes and walking pace (**Table 1**). The remaining unique variants resulted in

21 independent signals (i.e., *ATXN1, n*=8; *HTT, n*=6; *ATXN7, n*=3; *ATXN2, n*=2; *CACNA1A, n*=2)

referred to as haplotypes. The *HTT* haplotype two (index variant: intronic rs61348208), which we

have previously reported,[15] had the largest number of traits (*n*=6) associated with it, including both

pathogenic (e.g., depression) and non-pathogenic traits (e.g., aging traits and parental lifespan).

ATXN1 exhibited the highest number of independent signals (*n*=8 haplotypes), with *ATXN1*

haplotype three (index variant: intronic rs909788) (*n*=5) demonstrating the most trait associations.

However, these were all linked to highly correlated cognitive and socio-economic traits.

Profiling polyQ disorder genes for severe Mendelian diseases beyond canonical polyQ
disorders
A subset of the polyQ disorder genes (i.e., *AR, ATN1, ATXN2, CACNA1A, HTT, TBP*) had

phenotype entries in the OMIM database beyond the primary polyQ disorders (**Table 2**). Rare

Mendelian disorder associations included androgen insensitivity and hypospadias related to *AR*,
and neurological conditions linked to *HTT* (i.e., neurodevelopmental disorder: Lopes-Maciel-
Rodan syndrome), *CACNA1A* (i.e., developmental and epileptic encephalopathy) and *ATN1* (i.e.,
congenital hypotonia, epilepsy, developmental delay, and digital anomalies). *ATXN2* and *TBP*
were also associated with susceptibility to Parkinson's disease, a common neurological disorder,
while *ATXN2* was also associated with susceptibility to amyotrophic lateral sclerosis (ALS), a
neurodegenerative disease. Finally, *AR* was also associated with prostate cancer susceptibility in
OMIM. These findings illustrate that therapeutic polyQ disorder gene knockdown may impair
critical developmental or neurological pathways.

Analysis of human genomic safety profiles and the theoretical druggability of polyQ disorder
genes highlights potential safety concerns associated with therapeutic targeting

We evaluated genomic features that predict clinical trial success to better understand the theoretical
implications of therapeutically perturbing polyQ disorder genes. Most of these genes showed
unfavorable profiles based on multiple criteria (**Figure 3**) using thresholds defined by the original
study that identified associations with these features and clinical trial stoppage.[35] Notably, four
genes (i.e., *ATN1, ATXN1, ATXN7* and *HTT*) ranked unfavorably for the three categories associated
with clinical trial stoppage due to safety concerns (i.e., genetic constraint, broad expression, and
several interactors). Further, all polyQ disorder genes displayed at least one unfavorable signal for
one of these three features. All polyQ disorder genes, except for *THAP11*, displayed several
molecular interactors (i.e., more than ten protein-protein interactions in the IntAct database). This
was especially apparent for *HTT*, *ATXN1*, *ATN1* and *ATXN3*, which showed over 100 high-
confidence interactions (i.e., ten times above the threshold used for classification). While five
polyQ disorder genes fell within the *'druggable any'* category, this metric indicates whether the
gene can be theoretically perturbed, not an indicator of safety. Compared to HD age-of-onset
modifier genes, polyQ disorder genes displayed significantly more unfavorable features associated
with an increased safety risk ($P=7.03 \times 10^{-3}$; mean HD modifiers=1.0, n=9; mean polyQ
disorders=2.2, n=10; effect size r=0.628, large).

Discussion

Gene knockdown strategies targeting the primary disease-causing genes in polyQ disorders are being extensively explored as potential therapies in these repeat expansion disorders.[3,5,6,36] However, these strategies have been unsuccessful in polyQ clinical trials, failing to achieve the desired therapeutic value and resulting in adverse safety profiles. To better understand these challenges, we systematically profiled polyQ disorder genes using large-scale genomic databases, highlighting their pleiotropic roles and identifying genomic features associated with increased clinical trial failure. We demonstrated that polyQ disorder genes might be unfavorable targets since they are associated with genomic features linked to an increased failure of drug targets in clinical trials. Notably, *ATN1* (DRPLA), *ATXN1* (SCA1), *ATXN7* (SCA7), and *HTT* (HD) had particularly deleterious risk profiles in our analyses.

Our analysis of human GWAS revealed that polyQ disorder genes display extensive pleiotropy beyond their canonical roles in polyQ-related neurodegeneration, indicating potential on-target effects of therapeutic knockdown.[37] For example, *HTT, ATXN1, ATXN7* and *CACNA1A* were associated with neuropsychiatric disorders such as depression and schizophrenia. Additionally, metabolic traits like type 1 and type 2 diabetes were linked to *ATXN2* and *ATXN7*, which is in line with the fact that metabolic dysfunction is observed in several polyQ disorders.[38] *ATXN7* was exclusively associated with pathogenic traits, including schizophrenia, diabetes, breast cancer, and cataracts, highlighting the potential risks of targeting this gene. Our OMIM analyses also revealed disease links to polyQ disorder genes outside canonical repeat-mediated disorders. For example, *ATN1* and *HTT* have been linked to neurodevelopmental disorders, while *CACNA1A* has been linked to channelopathies with diverse neurological manifestations. However, susceptibility to Parkinson's disease and ALS are findings correlated with longer CAG repeats,[39] suggesting possible benefits of mutation-specific knockdown related to these phenotypes.

PolyQ disorder genes were also linked to critical non-pathogenic phenotypes through GWAS. We have previously reported that common *HTT* genetic variation is associated with important neurobiological traits such as educational attainment and longevity,[15] which we replicate here. This study showed that *ATXN1* is also linked to similar traits, including educational attainment and cognitive abilities. When comparing the variant effects between related GWAS and GTEx

expression, alleles linked to lower *ATXN1* expression were also associated with lower educational
attainment and decreased cognitive abilities. These findings suggest that therapeutically targeting
the wild-type versions of these genes might inadvertently affect cognitive function, which should
be assessed during future clinical trials. However, a key limitation of this investigation is that we
cannot currently infer the direction of effect for all polyQ gene-GWAS trait pairs. Future studies
should systematically address this gap using high-throughput approaches (e.g., CRISPR screens
and functional assays).

In addition to individual gene-trait associations, network analyses revealed that specific trait
associations were shared between polyQ disorder genes, with *ATXN1*, *ATXN2,* and *HTT* displaying
the greatest number of shared interactions. For example, associations with metabolic traits (type 2
diabetes and cholesterol levels) were shared by *HTT, ATXN2* and *ATXN7* and susceptibility to
breast cancer was shared by *ATXN1* and *ATXN7*. These analyses indicate that specific polyQ
disorder genes may be involved in common biological pathways, as previously reported by
others.[40,41]

While half of the polyQ disorder genes were found to be potentially challenging to target
therapeutically with traditional approaches, RNA-targeted therapeutics provide a flexible solution
by enabling the targeting of any gene product. Nonetheless, our human genomic safety profile
analyses revealed that polyQ disorder genes consistently rank unfavorably for predictors of clinical
trial success,[19] which could provide some insight into the mechanisms driving gene-lowering trial
failures.[6,7,42] Specifically, *ATN1*, *ATXN1*, *ATXN7* and *HTT* ranked poorly across all safety-related
categories. These four genes are integral to transcriptional regulation and are, therefore, essential
for several critical physiological processes.[38] Therapeutic targeting of these genes, especially using
approaches that do not specifically target mutant versions of the related gene products, could
therefore disrupt several important processes, leading to adverse effects.

Most of the polyQ disorder genes (i.e., 80%) displayed broad expression patterns, with this profile
of expression associated with increased trial stoppage risks [reported odds ratio (OR): 1.29 95%;
confidence interval (CI): 1.19-1.39].[19] Additionally, half of the polyQ disorder genes are highly
constrained, with LoF intolerance (pLI>0.9) also associated with an increased risk of trial stoppage

(reported OR: 1.37; 95% CI: 1.27-1.48).[19] Further, all polyQ disorder genes, except for *THAP11*,

displayed more than ten high-confidence protein-protein interactions, indicating their central

physiological roles – an effect that can, in part, be attributed to the polyQ repeats themselves.[43]

Specifically, genes with between 11 and 20 partners (e.g., *CACNA1A*) are at an increased risk of

clinical trial stoppage (reported OR: 1.31; 95% CI: 1.19-1.44),[19] while those with >20 partners

(i.e., 80% of polyQ disorder genes) are at an even greater risk (reported OR: 1.38; 95% CI: 1.26-

1.52).[19]

Finally, when we compared the genomic safety predictions for polyQ disorder genes to those of

genetic modifiers of HD onset age, we demonstrated that the modifier genes showed more

favourable genomic safety scores. This provides additional support for prioritizing these modifiers

in future therapeutic research, especially in HD. Beyond their favourable drug target profiles, a

benefit of modifier-based therapeutic targeting is the potential for cross-repeat expansion disorder

relevance due to shared pathobiological mechanisms of these modifier genes (e.g., somatic repeat

instability).[34,44–47] This may also be useful for rarer repeat expansion disorders, where assembling

large cohorts of individuals required for a disorder-specific clinical trial may be difficult.[36] While

these modifier genes were identified by GWAS-based approaches, which typically yield

associations with modest to small effect sizes with traits being studied,[34] the effect of

therapeutically targeting these genes may have a larger impact on disease course. This is illustrated

by the fact that several GWAS have confirmed the involvement of variants in known drug targets

for numerous diseases.[48] For example, *DRD2*, the target for antipsychotics, has now been robustly

associated with schizophrenia risk through GWAS, although with a small effect (rs2514218:

GWAS odds ratio = 1.08)[49].

In conclusion, our findings indicate that the pleiotropic roles and adverse genomic profiles of

polyQ disorder genes might diminish their potential as therapeutic targets for their respective

conditions. However, it should be noted that these genes do have human genetic evidence for

involvement in their primary diseases, a feature associated with increased clinical trial success.[13]

Therefore, polyQ disorder genes should not be entirely abandoned as therapeutic targets, especially

with some encouraging results from recent early clinical trials.[50] Instead, increased focus should

be placed on assessing age-dependent implications of knockdown, as well as therapeutic

approaches aimed at mutant allele-specific perturbation and gene editing. In parallel, building on our findings that genetic modifiers of the age of HD onset have favourable genomic safety scores, future research should intensively investigate therapeutics that target repeat expansion disorder genetic modifiers. In line with this, the promising role of therapeutic targets that prevent somatic expansions has been further emphasized by recent reports that show that the impact of the expanded repeat only becomes evident late in the lifetime of vulnerable cell types.[51] Taken together, this study has revealed the importance of incorporating diverse human genomics data into drug development pipelines to develop safer and more effective treatments.

Declaration of interest

The authors declare no competing interests.

Acknowledgements

We thank the Natural Sciences and Engineering Research Council of Canada through the Canada Research Chairs Initiative and Discovery Grant Program, as well as the Health Sciences Centre Foundation Winnipeg, for the financial support provided to GEBW. BID was also supported through the Canadian Institutes of Health Research Canada Research Chairs Initiative. The Research Manitoba Graduate Studentship and Rady Faculty of Health Sciences Student Top-Up supported NKL.

Author contributions

NKL performed the formal analyses and wrote the manuscript. GEBW and BD designed the study and wrote and edited the manuscript. All authors agreed on the final version of the paper.

REFERENCES

1. Bunting, E.L., Hamilton, J., and Tabrizi, S.J. (2022). Polyglutamine diseases. Curr Opin Neurobiol *72*, 39–47. https://doi.org/10.1016/j.conb.2021.07.001.

2. Fan, H.-C., Ho, L.-I., Chi, C.-S., Chen, S.-J., Peng, G.-S., Chan, T.-M., Lin, S.-Z., and Harn, H.-J. (2014). Polyglutamine (PolyQ) diseases: genetics to treatments. Cell Transplant *23*, 441–458. https://doi.org/10.3727/096368914X678454.

3. Ghanekar, S.D., Kuo, S.-H., Staffetti, J.S., and Zesiewicz, T.A. (2022). Current and emerging treatment modalities for spinocerebellar ataxias. Expert Rev Neurother *22*, 101–114. https://doi.org/10.1080/14737175.2022.2029703.

4. Stoker, T.B., Mason, S.L., Greenland, J.C., Holden, S.T., Santini, H., and Barker, R.A. (2022). Huntington's disease: diagnosis and management. Pract Neurol *22*, 32–41. https://doi.org/10.1136/practneurol-2021-003074.

5. Perlman, S.L. (2020). Update on the Treatment of Ataxia: Medication and Emerging Therapies. Neurotherapeutics *17*, 1660–1664. https://doi.org/10.1007/s13311-020-00941-3.

6. Rook, M.E., and Southwell, A.L. (2022). Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic. BioDrugs *36*, 105–119. https://doi.org/10.1007/s40259-022-00519-9.

7. Esteves, S., Duarte-Silva, S., and Maciel, P. (2017). Discovery of Therapeutic Approaches for Polyglutamine Diseases: A Summary of Recent Efforts. Med Res Rev *37*, 860–906. https://doi.org/10.1002/med.21425.

8. Kwon, D. (2021). Failure of genetic therapies for Huntington's devastates community. Nature *593*, 180. https://doi.org/10.1038/d41586-021-01177-7.

9. McColgan, P., Thobhani, A., Boak, L., Schobel, S.A., Nicotra, A., Palermo, G., Trundell, D., Zhou, J., Schlegel, V., Sanwald Ducray, P., et al. (2023). Tominersen in Adults with Manifest Huntington's Disease. N Engl J Med *389*, 2203–2205. https://doi.org/10.1056/NEJMc2300400.

10. Plenge, R.M. (2016). Disciplined approach to drug discovery and early development. Sci Transl Med *8*, 349ps15. https://doi.org/10.1126/scitranslmed.aaf2608.

11. Plenge, R.M., Scolnick, E.M., and Altshuler, D. (2013). Validating therapeutic targets through human genetics. Nat Rev Drug Discov *12*, 581–594. https://doi.org/10.1038/nrd4051.

12. Ghoussaini, M., Mountjoy, E., Carmona, M., Peat, G., Schmidt, E.M., Hercules, A., Fumis, L., Miranda, A., Carvalho-Silva, D., Buniello, A., et al. (2021). Open Targets Genetics: systematic identification of trait-associated genes using large-scale genetics and functional genomics. Nucleic Acids Res *49*, D1311–D1320. https://doi.org/10.1093/nar/gkaa840.

13. Minikel, E.V., Painter, J.L., Dong, C.C., and Nelson, M.R. (2024). Refining the impact of
genetic evidence on clinical success. Nature *629*, 624–629. https://doi.org/10.1038/s41586-
024-07316-0.

14. Schultz, J.L., Saft, C., and Nopoulos, P.C. (2021). Association of CAG Repeat Length in the
Huntington Gene With Cognitive Performance in Young Adults. Neurology *96*, e2407–
e2413. https://doi.org/10.1212/WNL.0000000000011823.

15. Slike, A.N., and Wright, G.E.B. (2022). Common huntingtin-related genetic variation is
associated with neurobiological and aging traits in humans. Cell Death Discov *8*, 311.
https://doi.org/10.1038/s41420-022-01114-1.

16. Ghoussaini, M., Nelson, M.R., and Dunham, I. (2023). Future prospects for human genetics
and genomics in drug discovery. Curr Opin Struct Biol *80*, 102568.
https://doi.org/10.1016/j.sbi.2023.102568.

17. Rusina, P.V., Falaguera, M.J., Romero, J.M.R., McDonagh, E.M., Dunham, I., and Ochoa,
D. (2023). Genetic support for FDA-approved drugs over the past decade. Nat Rev Drug
Discov *22*, 864. https://doi.org/10.1038/d41573-023-00158-x.

18. Zhang, X., Yu, W., Li, Y., Wang, A., Cao, H., and Fu, Y. (2024). Drug development
advances in human genetics-based targets. MedComm (2020) *5*, e481.
https://doi.org/10.1002/mco2.481.

19. Razuvayevskaya, O., Lopez, I., Dunham, I., and Ochoa, D. (2024). Genetic factors
associated with reasons for clinical trial stoppage. Nat Genet *56*, 1862–1867.
https://doi.org/10.1038/s41588-024-01854-z.

20. Nelson, M.R., Tipney, H., Painter, J.L., Shen, J., Nicoletti, P., Shen, Y., Floratos, A., Sham,
P.C., Li, M.J., Wang, J., et al. (2015). The support of human genetic evidence for approved
drug indications. Nat Genet *47*, 856–860. https://doi.org/10.1038/ng.3314.

21. Martin, F.J., Amode, M.R., Aneja, A., Austine-Orimoloye, O., Azov, A.G., Barnes, I.,
Becker, A., Bennett, R., Berry, A., Bhai, J., et al. (2023). Ensembl 2023. Nucleic Acids Res
51, D933–D941. https://doi.org/10.1093/nar/gkac958.

22. Mountjoy, E., Schmidt, E.M., Carmona, M., Schwartzentruber, J., Peat, G., Miranda, A.,
Fumis, L., Hayhurst, J., Buniello, A., Karim, M.A., et al. (2021). An open approach to
systematically prioritize causal variants and genes at all published human GWAS trait-
associated loci. Nat Genet *53*, 1527–1533. https://doi.org/10.1038/s41588-021-00945-5.

23. Amberger, J.S., Bocchini, C.A., Schiettecatte, F., Scott, A.F., and Hamosh, A. (2015).
OMIM.org: Online Mendelian Inheritance in Man (OMIM®), an online catalog of human
genes and genetic disorders. Nucleic Acids Res *43*, D789-798.
https://doi.org/10.1093/nar/gku1205.

24. de Sainte Agathe, J.-M., Filser, M., Isidor, B., Besnard, T., Gueguen, P., Perrin, A., Van
Goethem, C., Verebi, C., Masingue, M., Rendu, J., et al. (2023). SpliceAI-visual: a free

online tool to improve SpliceAI splicing variant interpretation. Hum Genomics *17*, 7.
https://doi.org/10.1186/s40246-023-00451-1.

25. Machiela, M.J., and Chanock, S.J. (2015). LDlink: a web-based application for exploring
population-specific haplotype structure and linking correlated alleles of possible functional
variants. Bioinformatics *31*, 3555–3557. https://doi.org/10.1093/bioinformatics/btv402.

26. Huyghe, J.R., Fransen, E., Hannula, S., Van Laer, L., Van Eyken, E., Mäki-Torkko, E.,
Aikio, P., Sorri, M., Huentelman, M.J., and Camp, G.V. (2011). A genome-wide analysis of
population structure in the Finnish Saami with implications for genetic association studies.
Eur J Hum Genet *19*, 347–352. https://doi.org/10.1038/ejhg.2010.179.

27. Karczewski, K.J., Francioli, L.C., Tiao, G., Cummings, B.B., Alföldi, J., Wang, Q., Collins,
R.L., Laricchia, K.M., Ganna, A., Birnbaum, D.P., et al. (2020). The mutational constraint
spectrum quantified from variation in 141,456 humans. Nature *581*, 434–443.
https://doi.org/10.1038/s41586-020-2308-7.

28. Lek, M., Karczewski, K.J., Minikel, E.V., Samocha, K.E., Banks, E., Fennell, T., O'Donnell-
Luria, A.H., Ware, J.S., Hill, A.J., Cummings, B.B., et al. (2016). Analysis of protein-coding
genetic variation in 60,706 humans. Nature *536*, 285–291.
https://doi.org/10.1038/nature19057.

29. Uhlén, M., Fagerberg, L., Hallström, B.M., Lindskog, C., Oksvold, P., Mardinoglu, A.,
Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015). Proteomics. Tissue-based
map of the human proteome. Science *347*, 1260419.
https://doi.org/10.1126/science.1260419.

30. Digre, A., and Lindskog, C. (2021). The Human Protein Atlas—Spatial localization of the
human proteome in health and disease. Protein Science *30*, 218–233.
https://doi.org/10.1002/pro.3987.

31. Ochoa, D., Hercules, A., Carmona, M., Suveges, D., Baker, J., Malangone, C., Lopez, I.,
Miranda, A., Cruz-Castillo, C., Fumis, L., et al. (2023). The next-generation Open Targets
Platform: reimagined, redesigned, rebuilt. Nucleic Acids Res *51*, D1353–D1359.
https://doi.org/10.1093/nar/gkac1046.

32. Villaveces, J.M., Jiménez, R.C., Porras, P., Del-Toro, N., Duesbury, M., Dumousseau, M.,
Orchard, S., Choi, H., Ping, P., Zong, N.C., et al. (2015). Merging and scoring molecular
interactions utilising existing community standards: tools, use-cases and a case study.
Database (Oxford) *2015*, bau131. https://doi.org/10.1093/database/bau131.

33. Freshour, S.L., Kiwala, S., Cotto, K.C., Coffman, A.C., McMichael, J.F., Song, J.J., Griffith,
M., Griffith, O.L., and Wagner, A.H. (2021). Integration of the Drug-Gene Interaction
Database (DGIdb 4.0) with open crowdsource efforts. Nucleic Acids Res *49*, D1144–D1151.
https://doi.org/10.1093/nar/gkaa1084.

34. Namuli, K.L., Slike, A.N., Hollebeke, M.A., and Wright, G.E.B. (2025). Genomic
characterization of Huntington's disease genetic modifiers informs drug target tractability.
Brain Communications 7, fcae418. https://doi.org/10.1093/braincomms/fcae418.

35. Razuvayevskaya, O., Lopez, I., Dunham, I., and Ochoa, D. (2024). Genetic factors
associated with reasons for clinical trial stoppage. Nat Genet, 1–6.
https://doi.org/10.1038/s41588-024-01854-z.

36. Coarelli, G., Coutelier, M., and Durr, A. (2023). Autosomal dominant cerebellar ataxias: new
genes and progress towards treatments. Lancet Neurol 22, 735–749.
https://doi.org/10.1016/S1474-4422(23)00068-6.

37. Nguyen, P.A., Born, D.A., Deaton, A.M., Nioi, P., and Ward, L.D. (2019). Phenotypes
associated with genes encoding drug targets are predictive of clinical trial side effects. Nat
Commun 10, 1579. https://doi.org/10.1038/s41467-019-09407-3.

38. Tandon, S., Aggarwal, P., and Sarkar, S. (2024). Polyglutamine disorders: Pathogenesis and
potential drug interventions. Life Sciences 344, 122562.
https://doi.org/10.1016/j.lfs.2024.122562.

39. Rajan-Babu, I.-S., Dolzhenko, E., Eberle, M.A., and Friedman, J.M. (2024). Sequence
composition changes in short tandem repeats: heterogeneity, detection, mechanisms and
clinical implications. Nat Rev Genet 25, 476–499. https://doi.org/10.1038/s41576-024-
00696-z.

40. Gui, H., Kwan, J.S., Sham, P.C., Cherny, S.S., and Li, M. (2017). Sharing of Genes and
Pathways Across Complex Phenotypes: A Multilevel Genome-Wide Analysis. Genetics 206,
1601–1609. https://doi.org/10.1534/genetics.116.198150.

41. Peng, J., Zhou, Y., and Wang, K. (2021). Multiplex gene and phenotype network to
characterize shared genetic pathways of epilepsy and autism. Sci Rep 11, 952.
https://doi.org/10.1038/s41598-020-78654-y.

42. Ward, J.M., Stoyas, C.A., Switonski, P.M., Ichou, F., Fan, W., Collins, B., Wall, C.E.,
Adanyeguh, I., Niu, C., Sopher, B.L., et al. (2019). Metabolic and Organelle Morphology
Defects in Mice and Human Patients Define Spinocerebellar Ataxia Type 7 as a
Mitochondrial Disease. Cell Rep 26, 1189-1202.e6.
https://doi.org/10.1016/j.celrep.2019.01.028.

43. Klockgether, T., Mariotti, C., and Paulson, H.L. (2019). Spinocerebellar ataxia. Nat Rev Dis
Primers 5, 24. https://doi.org/10.1038/s41572-019-0074-3.

44. Flower, M., Lomeikaite, V., Ciosi, M., Cumming, S., Morales, F., Lo, K., Hensman Moss,
D., Jones, L., Holmans, P., TRACK-HD Investigators, et al. (2019). MSH3 modifies somatic
instability and disease severity in Huntington's and myotonic dystrophy type 1. Brain 142,
1876–1886. https://doi.org/10.1093/brain/awz115.

45. Laabs, B.-H., Klein, C., Pozojevic, J., Domingo, A., Brüggemann, N., Grütz, K., Rosales,
R.L., Jamora, R.D., Saranza, G., Diesta, C.C.E., et al. (2021). Identifying genetic modifiers
of age-associated penetrance in X-linked dystonia-parkinsonism. Nat Commun *12*, 3216.
https://doi.org/10.1038/s41467-021-23491-4.

46. Bettencourt, C., Hensman-Moss, D., Flower, M., Wiethoff, S., Brice, A., Goizet, C.,
Stevanin, G., Koutsis, G., Karadima, G., Panas, M., et al. (2016). DNA repair pathways
underlie a common genetic mechanism modulating onset in polyglutamine diseases. Ann
Neurol *79*, 983–990. https://doi.org/10.1002/ana.24656.

47. Wright, G.E.B., Findlay Black, H., Collins, J.A., Gall-Duncan, T., Caron, N.S., Pearson,
C.E., and Hayden, M.R. (2020). Interrupting sequence variants and age of onset in
Huntington's disease: clinical implications and emerging therapies. Lancet Neurol *19*, 930–
939. https://doi.org/10.1016/S1474-4422(20)30343-4.

48. Visscher, P.M., Wray, N.R., Zhang, Q., Sklar, P., McCarthy, M.I., Brown, M.A., and Yang,
J. (2017). 10 Years of GWAS Discovery: Biology, Function, and Translation. Am J Hum
Genet *101*, 5–22. https://doi.org/10.1016/j.ajhg.2017.06.005.

49. Lam, M., Chen, C.-Y., Li, Z., Martin, A.R., Bryois, J., Ma, X., Gaspar, H., Ikeda, M.,
Benyamin, B., Brown, B.C., et al. (2019). Comparative genetic architectures of
schizophrenia in East Asian and European populations. Nat Genet *51*, 1670–1678.
https://doi.org/10.1038/s41588-019-0512-x.

50. Farag, M., Tabrizi, S.J., and Wild, E.J. (2024). Huntington's Disease Clinical Trials Update:
September 2024. Journal of Huntington's Disease *13*, 409–418.
https://doi.org/10.1177/18796397241293955.

51. Handsaker, R.E., Kashin, S., Reed, N.M., Tan, S., Lee, W.-S., McDonald, T.M., Morris, K.,
Kamitaki, N., Mullally, C.D., Morakabati, N.R., et al. (2025). Long somatic DNA-repeat
expansion drives neurodegeneration in Huntington's disease. Cell *0*.
https://doi.org/10.1016/j.cell.2024.11.038.

Figures, titles and legends

Figure 1. PolyQ disorder genes are pleiotropic and associated with several human traits and diseases in diverse phenotypic categories. (A) polyQ-associated genes and their corresponding polyQ disorders. Colors represent different genes used across panels and figures. **(B)** Human traits and disorders linked to polyQ disorder genes (i.e., L2G>0.5) obtained from an analysis of genome wide association studies in the Open Targets Genetics Database. The highest number of gene-trait pairs were identified for *ATXN1*, *ATXN2*, and *HTT* and most traits were classified as measurements. **(C)** Heatmap of non-measurement-related traits (L2G>0.5) for each polyQ disorder gene, depicting several associations for disease including those related to cardiovascular system (e.g., atrial fibrillation), pancreas (e.g., type 2 and type 2 diabetes) and nervous system. **(D)** Network graph illustrating shared polyQ disorder gene-trait associations. Larger circles represent the number of traits associated with a particular gene, while thicker arcs indicate more shared trait associations between genes. Notable shared traits include *HTT* and *ATXN1* with educational attainment and cognitive ability; *ATXN1* and *ATXN7* with breast cancer; and *ATXN1*, *ATXN2* and *ATXN3* with HDL cholesterol levels. This network highlights the pleiotropic effects of polyQ disorder genes across neurological, metabolic, and oncological traits. **Abbreviations:** L2G; locus-to-gene; *DRPLA*, Dentatorubral-Pallidoluysian Atrophy; *HD*, Huntington Disease; *SBMA*, Spinal and Bulbar Muscular Atrophy; *SCA*, Spinocerebellar Ataxia.

Figure 2. High-confidence and informative human gene-trait associations linked to the polyQ disorder genes. (A) A total of 46 traits linked to five polyQ disorder genes remained after applying a filtering threshold of L2G>0.5, while excluding count-based terms (e.g., blood cell counts) and studies lacking PubMed IDs. **(B)** L2G scores for individual high confidence trait associations (duplicate traits removed). PolyQ disorder genes exhibit associations with both pathogenic and non-pathogenic characteristics, across neurological, metabolic, and immune-related traits. **(C)** *HTT* and **(D)** *ATXN1* displayed the highest number of gene-trait pairs and are linked to neurological disorders and neurobiological phenotypes. In these panels, high confidence gene-trait associations are annotated and plotted by variant position and L2G score. Color indicates predicted variant consequence (*most severe*) of index variant for each trait association. Count based traits were plotted but not annotated. The grey-shaded segment represents polyQ disorder gene locus (GRCh38-genome build coding sequence start-stop position). **Abbreviations:** L2G; locus-to-gene, UTR; Untranslated region, GRCh38; Genome Reference Consortium Human Reference 38.

174
175

Figure 3. Genetic features associated with clinical trial success suggest that polyQ disorder genes may not be favorable therapeutic targets. (**A**) Genetic constraint features, gnomAD probability of loss-of-function intolerance (pLI) and negative observed vs expected loss-of-function variant ratio, indicate high levels of the constraint of the polyQ disorder genes. pLI allows non-constrained genes (pLI<0.1) to be differentiated from highly constrained ones (pLI>0.9). The observed/expected ratio is a quantitative measure of how tolerant the genes are to certain classes of variations. (**B**) Tissue specificity of the polyQ disorder genes, with *AR* and *CACNA1A* displaying tissue-enhanced and tissue-enriched, respectively, while others show low specificity. (**C**) PolyQ disorder genes interact with several other proteins and only *THAP11* displays less than 11 interacting partners (associated with decreased levels of clinical trial stoppage). (**D**) Aggregated summary of human genomic features used to rank the theoretical druggability and genomic safety of polyQ disorder genes. Genes ranked more unfavorable related to theoretical druggability and genomic safety, such as *HTT*, *ATN1*, *ATXN1* and *ATXN7*, are on the right of the plot. Individual favorable metrics are represented by the teal green tiles, while the deep purple tiles represent unfavorable features. Favorable/unfavorable classification thresholds are based on metrics identified by original study where features associated with clinical trial stoppage were identified (Razuvayevskaya *et al.* 2024 *Nat Gen*). (**E**) PolyQ disorder genes (yellow) display significantly more (*P*=0.007) unfavorable genomic safety scores based on constraint, tissue specificity and interactions (maximum score=3, increased risk of clinical trial stoppage) than Huntington disease modifier genes (blue). Mean scores are indicated by red line (mean polyQ=2.2, mean HD modifier genes=1.0).

Tables

Table 1 High-confidence GWAS associations linked to polyQ disorder genes are associated with pathogenic and non-pathogenic human traits. L2G prioritization highlights traits linked to unique independent signals identified as haplotypes associated with polyQ disorder genes extending beyond the primary traits directly caused by the pathogenic CAG repeat expansions in these the genes.

Signal (Tag variant)[a]	Reported trait (PMID)	Variant ID	Annotation[b]	Effect AF EUR[c]	GWAS index P-value	GWAS index effect (95% CI)	L2G	CADD score
ATXN1: haplotype one (rs719316)	Multiple sclerosis (31604244)	rs719316	intronic	T: 0.529	2.00×10^{-13}	1.07 (1.05-1.09)[d]	0.79	5.92
ATXN1: haplotype two (rs17603856)	Systemic lupus erythematosus (27399966)	rs17603856	intronic	G: 0.346	3.00×10^{-12}	0.88 (0.85-0.91)[d]	0.79	10.94
ATXN1: haplotype three (rs909788)	Cognitive ability, years of educational attainment or schizophrenia (31374203)	rs6459480	intronic	A: 0.509	2.00×10^{-10}	NA	0.69	1.82
	Household income (31844048)	rs6459480	intronic	A: 0.509	5.00×10^{-10}	-0.01 (-0.02--0.01)	0.70	1.82
	Educational attainment (30038396)	rs9297016	intronic	G: 0.576	1.00×10^{-09}	-0.01 (-0.01--0.006)	0.68	2.57
	Educational attainment: years of education (27225129)	rs7772172	intronic	G: 0.576	1.00×10^{-08}	-0.01 (-0.02--0.01)	0.68	5.02

	Educational attainment (years of education) (30038396)	rs909788	intronic	C: 0.545	4.00×10^{-08}	-0.01 (-0.011--0.005)	0.77	5.75
ATXN1: haplotype four (rs6459472)	Central corneal thickness (32528159)	rs6459472	intronic	G: 0.573	3.00×10^{-09}	NA	0.72	2.97
ATXN1: haplotype five (rs9367926)	Male-pattern baldness (30573740)	rs6915310	intronic	T: 0.182	5.00×10^{-20}	0.04 (0.03 - 0.05)	0.72	4.27
	Balding type 1 (30595370)	rs9367926	intronic	G: 0.180	6.00×10^{-12}	NA	0.71	6.59
ATXN1: haplotype six (rs2237199)	Subcutaneous adipose tissue attenuation (27918534)	rs2237199	intronic	A: 0.112	1.00×10^{-08}	5.67 (3.73 - 7.61)	0.57	3.49
ATXN1: haplotype seven (rs7770062)	Atrial fibrillation (30061737)	rs73366713	intronic	A: 0.131	1.53×10^{-25}	0.90 (0.88-0.92)[d]	0.55	2.84
	Atrial fibrillation (29892015)	rs7770062	intronic	A: 0.131	9.00×10^{-21}	0.90 (0.88-0.92)[d]	0.54	2.33
ATXN1: haplotype eight (rs3819405)	Breast cancer (29059683)	rs3819405	intronic	T: 0.340	1.65×10^{-08}	0.96 (0.95-0.97)[d]	0.53	12.10
ATXN2: haplotype one (rs653178)	Celiac disease (20190752)	rs653178	intronic	T: 0.534	6.00×10^{-14}	0.83 (0.78-0.87)[d]	0.51	1.59
ATXN2: haplotype two (rs848130)	Type 1 diabetes (34012112)	rs848130	intronic	A: 0.192	1.60×10^{-14}	0.85 (0.82-0,89)[d]	0.67	2.02
ATXN7: haplotype one (rs832190)	Schizophrenia (31740837)	rs832190	intronic	T: 0.603	4.00×10^{-08}	NA	0.51	0.58

Gene: haplotype	Trait (PMID)	rsID	Annotation	Allele: freq	P-value	Effect (95% CI)		
ATXN7: haplotype two (rs3821902)	Breast cancer (29059683)	rs3821902	intronic	G: 0.150	2.99×10^{-12}	1.06 (1.05-1.08)[d]	0.54	0.81
ATXN7: haplotype three (rs13434089)	Type 2 diabetes (32541925)	rs13434089	intronic	C: 0.141	4.00×10^{-31}	-0.06 (-0.07--0.05)	0.55	4.59
CACNA1A: haplotype one (rs5021328)	Appendicular lean mass (33097823)	rs5021328	intronic	C: 0.644	6.60×10^{-09}	-0.01 (-0.02--0.01)	0.86	0.63
CACNA1A: haplotype two (rs16003)	Positive affect (30643256)	rs16003	intronic	T: 0.463	3.00×10^{-08}	0.01 (0.00 - 0.01)	0.84	8.26
	Depressive symptoms (30643256)	rs16003	intronic	T: 0.463	3.00×10^{-08}	0.01 (0.00 - 0.01)	0.84	8.26
HTT: haplotype one (rs363096)	Noncognitive aspects of educational attainment (33414549)	rs363096	splice	C: 0.591	1.00×10^{-12}	0.05 (0.04 - 0.06)	0.72	6.29
	Educational attainment: years of education (30595370)	rs363096	splice	C: 0.591	1.00×10^{-10}	NA	0.74	6.29
HTT: haplotype two (rs61348208)	Depression (30718901)	rs7685686	intronic	G: 0.433	6.00×10^{-15}	0.983 (0.979-0.987)[d]	0.59	6.39
	Frailty index (34431594)	rs82334	intronic	C: 0.323	3.10×10^{-10}	-0.02 (-0.03--0.02)	0.54	4.13
	Parental lifespan (30642433)	rs61348208	intronic	T: 0.389	6.00×10^{-09}	0.23 (0.15 - 0.31)	0.63	5.46

	Trait (PMID)	rsID	Variant type	Allele	p-value	Effect (CI)		
	Gastroesophageal reflux disease (34187846)	rs7685686	intronic	G: 0.433	1.10×10^{-08}	0.97 (0.96-0.98)[d]	0.54	6.39
	Aging traits: health span, parental lifespan or longevity (32678081)	rs61348208	intronic	T: 0.389	3.00×10^{-08}	NA	0.62	5.46
	Vertex-wise sulcal depth (34910505)	rs2071703	intronic	C: 0.325	3.00×10^{-08}	5.57 (3.60 - 7.54)	0.6	2.52
HTT: haplotype three (rs113928896)	Highest math class taken (30038396)	rs113928896	intronic	T: 0.143	2.00×10^{-09}	0.02 (0.01 - 0.02)	0.55	0.32
HTT: haplotype four (rs362307)	Automobile speeding propensity (30643258)	rs362307	UTR	T: 0.063	6.00×10^{-14}	-0.03 (-0.04--0.02)	0.51	3.23
	Worry/vulnerability: special factor of neuroticism (30867560)	rs362307	UTR	T: 0.063	1.00×10^{-09}	0.01 (0.005 - 0.011)	0.54	3.23
	Walking pace (33128006)	rs362307	UTR	T: 0.063	1.00×10^{-09}	-0.01 (-0.02--0.01)	0.54	3.23
	Type 2 diabetes (30297969)	rs362307	UTR	T: 0.063	1.00×10^{-09}	1.08 (1.05-1.11)[d]	0.54	3.23
	Predicted visceral adipose tissue (31501611)	rs362307	UTR	T: 0.063	2.00×10^{-09}	0.03 (0.02 - 0.04)	0.54	3.23
HTT: haplotype five (rs6828882)	Monobrow (27182965)	rs6828882	intronic	G: 0.101	1.00×10^{-22}	NA	0.53	8.54

		rs2798297	intronic	A: 0.353	1.00x10^{-24}	NA	0.52	2.08
HTT: haplotype six (rs2798297)	Metabolic biomarkers (33980691)							

Haplotype, Group of variants in high LD with one another. Tag variant, Variant proxy for all variants in high LD at a haplotype. [a]LDlink SNPclip pruned signals using an r2 of 0.5 in the 1000 Genomes Project European superpopulations. [b]Ensembl VEP 'most severe' annotations. [c]1000 Genomes Project European superpopulation effect allele frequency. [d]Odds ratio (all other effects are beta estimates). **Abbreviations:** AF, Allele frequency; CADD, Combined Annotation Dependent Depletion; EUR, 1000 Genomes European super-population; L2G, Open Targets locus-to-gene scoring metric; NA, data Not available; PMID, PubMed Identifier; UTR, Untranslated region.

Table 2. Non-canonical disease associations of polyQ disorder genes potentially informs off target effects of therapeutic knockdown of pathogenic disease genes. Six polyQ disorder genes have OMIM phenotype entries outside of their main polyQ disorder. These phenotypes range from endocrine and metabolic conditions (e.g., androgen insensitivity), to neurological and neurodevelopmental disorders (e.g., developmental and epileptic encephalopathy, Lopes-Maciel-Rodan syndrome), and susceptibility to complex diseases.

Gene	OMIM phenotypes
AR	• Androgen insensitivity, partial, with or without breast cancer (MIM: 312300, X-linked recessive) • Androgen insensitivity (MIM: 300068, X-linked recessive) • Hypospadias 1, X-linked (MIM:300633, X-linked recessive) • *Susceptibility to: Prostate cancer (MIM: 176807, autosomal dominant, somatic mutation)*
ATN1	• Congenital hypotonia, epilepsy, developmental delay, and digital anomalies (MIM: 618494, autosomal dominant)
ATXN2	• *Susceptibility to: Amyotrophic lateral sclerosis (MIM: 183090, autosomal dominant)*[*] • *Susceptibility to: Parkinson disease, late-onset (MIM: 168600, autosomal dominant, multifactorial)*[*]
CACNA1A	• Developmental and epileptic encephalopathy 42 (MIM: 617106, autosomal dominant) • Episodic ataxia, type 2 (MIM: 108500, autosomal dominant)[*] • Migraine, familial hemiplegic, 1, with progressive cerebellar ataxia (MIM: 141500, autosomal dominant)
HTT	• Lopes-Maciel-Rodan syndrome (MIM: 617435, autosomal recessive)
TBP	• *Susceptibility to: Parkinson disease (MIM: 168600, autosomal dominant, multifactorial)*[*]

[*]CAG repeat mediated disorder/susceptibility. **Abbreviations: OMIM**, Online Mendelian Inheritance in Man